WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000062075) UBIQUITIN CROSS-REACTIVE PROTEIN AS A PROGNOSTIC MARKER FOR TUMOR CELL CHEMOSENSITIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/062075    International Application No.:    PCT/US2000/009959
Publication Date: 19.10.2000 International Filing Date: 13.04.2000
Chapter 2 Demand Filed:    13.11.2000    
IPC:
G01N 33/50 (2006.01), G01N 33/68 (2006.01)
Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, NJ 08903 (US) (For All Designated States Except US).
DESAI, Shyamal, D. [US/US]; (US) (For US Only).
LIU, Leroy, Fong [US/US]; (US) (For US Only).
LAVOIE, Edmond, J. [US/US]; (US) (For US Only)
Inventors: DESAI, Shyamal, D.; (US).
LIU, Leroy, Fong; (US).
LAVOIE, Edmond, J.; (US)
Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US)
Priority Data:
60/129,063 13.04.1999 US
60/157,745 05.10.1999 US
Title (EN) UBIQUITIN CROSS-REACTIVE PROTEIN AS A PROGNOSTIC MARKER FOR TUMOR CELL CHEMOSENSITIVITY
(FR) PROTEINE A ACTIVITE CROISEE AVEC L'UBIIQUITINE, UTILISEE COMME MARQUEUR DE LA CHIMIOSENSIBILITE DE CELLULES TUMORALES
Abstract: front page image
(EN)The present invention relates to methods for identifying cells with increased sensitivity to treatment with cytotoxic agents. The invention also relates to method for identifying cells with abnormal proteolytic processing mechanisms. More specifically, the invention relates to a method of using ubiquitin cross-reactive protein as a prognostic marker for tumor cells with enhanced sensitivity to treatment with DNA-damaging agents, including camptothecin and its analogs.
(FR)Cette invention concerne des méthodes d'identification de cellules qui présentent une sensibilité accrue à un traitement aux agents cytotoxiques, ainsi qu'une méthode d'identification de cellules caractérisées par des mécanismes de transformation protéolytiques anormaux. Plus précisément, l'invention a trait à une méthode qui fait intervenir une protéine à activité croisée avec l'ubiquitine comme marqueur, à des fins de pronostic, de cellules tumorales qui présentent une sensibilité marquée pour un traitement avec des agents endommageant l'ADN, dont la camptothécine et ses analogues.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)